𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lymphoproliferative disorders in chronic hepatitis C

✍ Scribed by R. Idilman; A. Colantoni; N. De Maria; S. Alkan; S. Nand; D. H. Van Thiel

Book ID
108885660
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
73 KB
Volume
11
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Lymphoproliferative disorders in individ
Lymphoproliferative disorders in individuals with chronic hepatitis b and C in the Turkish population
✍ Ramazan Idilman; Yusuf Bozkus; Guldane Seval; Dilsa Mizrak; Kubilay Cinar; Yusuf πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 87 KB

## Abstract The aims of this cohort study were to evaluate the association of malignant lymphoproliferative disorders in patients with chronic viral hepatitis and to compare the results with those in individuals with non‐alcoholic fatty liver disease. A total of 3,873 patients with chronic liver di

Infection of B cells with hepatitis C vi
Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C
✍ Momoko Inokuchi; Takayoshi Ito; Manabu Uchikoshi; Yuu Shimozuma; Kenichi Morikaw πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 214 KB πŸ‘ 1 views

## Abstract Infection with hepatitis C virus (HCV) is associated with lymphoproliferative disorders, represented by essential mixed cryoglobulinemia and B‐cell non‐Hodgkin's lymphoma, but the pathogenic mechanism remains obscure. HCV may infect B cells or interact with their cell surface receptors,

Hepatitis C virus infection and lymphopr
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation
✍ Nizar N. Zein; Rogelio G. Perez; Russel H. Wiesner πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 34 KB πŸ‘ 2 views

with treatment failures moving on to combination therapy (IFN/CMB). The primary difference between the two best strategies (IFN/CBM vs. CMB-G) was that the CMB-G strategy was more successful with those with genotype 1. Thus, the genotyping strategy reached more people with less responsive disease th